Consensus Corbus Pharmaceuticals Holdings, Inc. Deutsche Boerse AG

Stocks

3371

US21833P3010

Biotechnology & Medical Research

Market Closed - Deutsche Boerse AG 14:17:12 2026-10-01 EDT			5-day change	1st Jan Change
5.510 ^EUR	-0.99%		-17.02%	-17.14%

09-14	Corbus Pharmaceuticals Holdings, Inc. - Special Call
09-14	Corbus Pharma Reports Positive Top-Line Data From Weight-Loss Drug Study	DJ

a7520b19dfb0985ada3426c213.mdLAKYnAvYlkt9lrTuJKmly3uoox2rpWBn2vrtdhvTw.zIGJQfyWkNtX4L0nY4l8ygv94-tE7o9kYhXLwJo102Tou6dr5bPT-jfUvg~8d39a67920a90d9b88480e50cb2147b6

Analysts' recommendations: Corbus Pharmaceuticals Holdings, Inc.

08-13	Mizuho Adjusts PT on Corbus Pharmaceuticals to $33 From $34, Keeps Outperform Rating	MT
08-07	Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating	MT
06-23	Mizuho Securities Cuts Price Target on Corbus Pharmaceuticals to $34 From $44, Maintains Outperform Rating	MT
06-17	Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $52 From $54, Maintains Outperform Rating	MT
05-22	Mizuho Adjusts Price Target on Corbus Pharmaceuticals to $44 From $40, Maintains Outperform Rating	MT
05-13	Oppenheimer Adjusts Price Target on Corbus Pharmaceuticals to $54 From $57, Maintains Outperform Rating	MT
04-29	Mizuho Keept Price Target on Corbus Pharmaceuticals to $40, Maintains Outperform Rating	MT
04-29	Mizuho Adjusts Price Target on Corbus Pharmaceuticals to $40 From $39, Maintains Outperform Rating	MT
04-29	Guggenheim Initiates Corbus Pharmaceuticals at Buy With $45 Price Target	MT
04-02	Mizuho Lifts Price Target on Corbus Pharmaceuticals Holdings to $40 From $39, Keeps Outperform Rating	MT
11-13	RBC Trims Price Target on Corbus Pharmaceuticals Holdings to $53 From $55, Keeps Outperform, Speculative Risk	MT
25-10-20	Wedbush Raises Price Target on Corbus Pharmaceuticals Holdings to $38 From $31, Keeps Outperform Rating	MT
25-10-18	Corbus Pharmaceuticals Holdings, Inc. Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25	CI
25-10-14	Corbus Pharmaceuticals Holdings Inc. to Present CRB-701 Phase 1/2 Data At ESMO 2025	CI
25-05-20	Mizuho Securities Adjusts Corbus Pharmaceuticals Price Target to $32 From $42, Maintains Outperform Rating	MT
25-05-20	Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $32 From $42, Keeps Outperform Rating	MT
25-05-07	RBC Cuts Price Target on Corbus Pharmaceuticals Holdings to $58 From $65, Keeps Outperform, Speculative Risk	MT
25-02-28	William Blair Initiates Corbus Pharmaceuticals at Outperform	MT
24-09-24	Mizuho Cuts Price Target on Corbus Pharmaceuticals Holdings to $42 From $74, Keeps Outperform Rating	MT
24-09-23	B. Riley Cuts Price Target on Corbus Pharmaceuticals Holdings to $40 From $85, Keeps Buy Rating	MT
24-09-20	Top Midday Decliners	MT
24-09-20	Wedbush Cuts Corbus Pharmaceuticals Price Target to $51 From $85, Maintains Outperform Rating; Shares Tumble	MT
24-08-27	Mizuho Initiates Corbus Pharmaceuticals at Outperform With $74 Price Target	MT
24-08-07	Oppenheimer Adjusts Corbus Pharmaceuticals Price Target to $88 From $80, Maintains Outperform Rating	MT
24-07-30	Wedbush Initiates Corbus Pharmaceuticals at Outperform With $85 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+21.92%
	LONZA GROUP AG					+19.64%
	IQVIA HOLDINGS INC.					+7.4%
	REVOLUTION MEDICINES, INC.					+25.43%
	BEONE MEDICINES AG					+18.27%
	CELLTRION, INC.					+50.7%
	WUXI BIOLOGICS (CAYMAN) INC.					+3.91%
	INSMED INCORPORATED					+73.24%
	Average					+25.81%
	Weighted average by Cap.					+22.20%